Dr Linda Mileshkin

Honorary Associate
NHMRC Clinical Trials Centre, Sydney Medical School

Telephone 03 9656 1697


Selected grants


  • ICON9: An international phase III randomised study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy; Mileshkin L; University College London/Research Support.


  • ICON9: A phase 3 randomised trial of cediranib and olaparib maintenance in patients with relapsed platinum sensitive ovarian cancer; Mileshkin L, Brand A, Ledermann J, Rischin D, Beale P, Quinn M, Coward J, Viney R, Martyn J; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.


  • A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The OUTBACK trial; Mileshkin L, Narayan K, Rischin D, Quinn M, Friedlander M, Moore K, Kitchener H, Shrivastava S, Martyn J, Small Jnr W; National Health and Medical Research Council (NHMRC)/Project Grants.


  • PORTEC-3 - the role of adjuvant chemotherapy in high-risk endometrial cancer; Mileshkin L, Quinn M, Khaw P, Stockler M, Brand A, Martyn J, Sjoquist K, Creutzberg C; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.

To update your profile click here. For support on your academic profile contact .